MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 412532 | Name: Cefpodoxime free acid
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cefpodoxime is an oral, third-generation cephalosporin antibiotic. It is active against both Gram-positive and Gram-negative organisms with notable exceptions including Pseudomonas aeruginosa, Enterococcus, and Bacteroides fragilis. It is typically used to treat acute otitis media, pharyngitis, sinusitis, and gonorrhea. Cefpodoxime inhibits peptidoglycan synthesis in bacterial cell walls. It has an oral bioavailability of approximately 50%, which is increased when taken with food. It has an elimination half-life of 2-3 hours in adults, which is prolonged in renal failure. Approved indications include community acquired pneumonia, uncomplicated skin and skin structure infections, and uncomplicated urinary tract infections.

Chemical Structure

Cefpodoxime free acid
Cefpodoxime free acid
CAS#80210-62-4 (free acid)

Theoretical Analysis

MedKoo Cat#: 412532

Name: Cefpodoxime free acid

CAS#: 80210-62-4 (free acid)

Chemical Formula: C15H17N5O6S2

Exact Mass: 427.0620

Molecular Weight: 427.45

Elemental Analysis: C, 42.15; H, 4.01; N, 16.38; O, 22.46; S, 15.00

Price and Availability

Size Price Availability Quantity
25mg USD 350.00 2 Weeks
50mg USD 550.00 2 Weeks
100mg USD 850.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
80210-62-4 (free acid) 82619-04-3 (sodium) 87239-81-4 (Proxetil) 79287-88-0 (HCl) 82623-37-8 (TFA)
Synonym
Cefpodoxime free acid; R 3746; R-3746; R3746; R 3763; R-3763; R3763; U 76253A; U-76253A; U76253A;
IUPAC/Chemical Name
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-(methoxymethyl)-8-oxo-, (6R-(6alpha,7beta(Z)))-
InChi Key
WYUSVOMTXWRGEK-HBWVYFAYSA-N
InChi Code
InChI=1S/C15H17N5O6S2/c1-25-3-6-4-27-13-9(12(22)20(13)10(6)14(23)24)18-11(21)8(19-26-2)7-5-28-15(16)17-7/h5,9,13H,3-4H2,1-2H3,(H2,16,17)(H,18,21)(H,23,24)/b19-8-/t9-,13-/m1/s1
SMILES Code
O=C(C(N12)=C(COC)CS[C@]2([H])[C@H](NC(/C(C3=CSC(N)=N3)=N\OC)=O)C1=O)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 427.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Mahmood W, Ahmad I, Khan MA, Ali Shah SA, Ashraf M, Shahzad MI, Pervaiz I, Sajid-Ur-Rehman M, Khurshid U. Synthesis, characterization, molecular docking and biological evaluation of Schiff Base derivatives of cefpodoxime. Heliyon. 2022 Nov 2;8(11):e11332. doi: 10.1016/j.heliyon.2022.e11332. PMID: 36387450; PMCID: PMC9649975. 2: Gao YY, Sang KN, Li PP, Hao J, Zhang C, Li HJ, Zhou DG. Bioequivalence of two tablet formulations of cefpodoxime proxetil in beagle dogs. Front Vet Sci. 2022 Oct 14;9:1048823. doi: 10.3389/fvets.2022.1048823. PMID: 36311679; PMCID: PMC9614231. 3: Gupta A, Malik S, Kaminski M, Landman D, Quale JM. In Vitro and In Vivo Activity of Amoxicillin-Clavulanate Combined with Ceftibuten or Cefpodoxime Against Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae. Microb Drug Resist. 2022 Apr;28(4):419-424. doi: 10.1089/mdr.2021.0025. PMID: 35451880. 4: Yurtdaş-Kırımlıoğlu G. Spray dried nanospheres for inclusion complexes of cefpodoxime proxetil with β-cyclodextrin, 2-hydroxypropyl-β-cyclodextrin and methyl-β-cyclodextrin: improved dissolution and enhanced antibacterial activity. Drug Dev Ind Pharm. 2021 Aug;47(8):1261-1278. doi: 10.1080/03639045.2021.1989452. Epub 2021 Oct 15. PMID: 34606394. 5: Birgy A, Madhi F, Jung C, Levy C, Cointe A, Bidet P, Hobson CA, Bechet S, Sobral E, Vuthien H, Ferroni A, Aberrane S, Cuzon G, Beraud L, Gajdos V, Launay E, Pinquier D, Haas H, Desmarest M, Dommergues MA, Cohen R, Bonacorsi S; Group of the National Observatory of Urinary tract Infection due to ESBL-producing Enterobacteriaceae in children. Clavulanate combinations with mecillinam, cefixime or cefpodoxime against ESBL-producing Enterobacterales frequently associated with blaOXA-1 in a paediatric population with febrile urinary tract infections. J Antimicrob Chemother. 2021 Oct 11;76(11):2839-2846. doi: 10.1093/jac/dkab289. PMID: 34453533. 6: Sharma PK, Shukla VK, Kumar A. Physical Characterization and In Vitro Evaluation of Dissolution Rate from Cefpodoxime Proxetil Loaded Self Solidifying Solid SNEDDS. Curr Drug Deliv. 2022;19(3):395-406. doi: 10.2174/1567201818666210805153859. PMID: 34353259. 7: Dey KK, Ghosh M. Study of the structure and dynamics at various parts of the antibacterial drug molecule cefpodoxime proxetil. Solid State Nucl Magn Reson. 2021 Oct;115:101752. doi: 10.1016/j.ssnmr.2021.101752. Epub 2021 Jul 29. PMID: 34340119. 8: Yurtdaş-Kırımlıoğlu G. Development and characterization of lyophilized cefpodoxime proxetil-Pluronic® F127/polyvinylpyrrolidone K30 solid dispersions with improved dissolution and enhanced antibacterial activity. Pharm Dev Technol. 2021 Apr;26(4):476-489. doi: 10.1080/10837450.2021.1889584. Epub 2021 Mar 1. PMID: 33616480. 9: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Cefpodoxime. 2021 Jan 18. PMID: 30000458. 10: Wenzel M, Welte MN, Theissen LH, Wittler C, Hoeh B, Humke C, Preisser F, Würnschimmel C, Tilki D, Graefen M, Roos FC, Becker A, Karakiewicz PI, Chun FKH, Kluth LA, Mandel P. Comparison of Complication Rates with Antibiotic Prophylaxis with Cefpodoxime Versus Fluoroquinolones After Transrectal Prostate Biopsy. Eur Urol Focus. 2021 Sep;7(5):980-986. doi: 10.1016/j.euf.2020.11.006. Epub 2020 Dec 24. PMID: 33358884. 11: Shapiro AB, Moussa SH, Carter NM, Gao N, Miller AA. Ceftazidime-Avibactam Resistance Mutations V240G, D179Y, and D179Y/T243M in KPC-3 β-Lactamase Do Not Alter Cefpodoxime-ETX1317 Susceptibility. ACS Infect Dis. 2021 Jan 8;7(1):79-87. doi: 10.1021/acsinfecdis.0c00575. Epub 2020 Dec 8. PMID: 33291867. 12: Das N, Chadda RK. Hyperprolactinemic Galactorrhea Associated With Cefpodoxime in a Patient With Recurrent Depressive Disorder on Venlafaxine Monotherapy: A Case Report. J Clin Psychopharmacol. 2020 Nov/Dec;40(6):635-636. doi: 10.1097/JCP.0000000000001293. PMID: 33065718. 13: Quan J, Ma C, Wang Y, Hu B, Zhang D, Zhang Z, Wang J, Cheng M. Repurposing of cefpodoxime proxetil as potent neuroprotective agent through computational prediction and in vitro validation. J Biomol Struct Dyn. 2021 Jul;39(11):3975-3985. doi: 10.1080/07391102.2020.1772884. Epub 2020 Jun 8. PMID: 32448083. 14: Fan Y, Chen H, Huang Z, Zhu J, Wan F, Peng T, Pan X, Huang Y, Wu C. Taste- masking and colloidal-stable cubosomes loaded with Cefpodoxime proxetil for pediatric oral delivery. Int J Pharm. 2020 Feb 15;575:118875. doi: 10.1016/j.ijpharm.2019.118875. Epub 2019 Nov 22. PMID: 31765781. 15: Babu T, Panachiyil GM, Sebastian J, Shastry V. Drug Rash With Eosinophilia and Systemic Symptoms (DRESS) Syndrome Probably Related to Cefpodoxime: A Case Report. J Pharm Pract. 2021 Feb;34(1):163-165. doi: 10.1177/0897190019866094. Epub 2019 Aug 5. PMID: 31382812. 16: Pieper M, Schleich H, Gröger H. Isolation and characterization of side- products formed through ∆2-isomerization in the synthesis of cefpodoxime proxetil. J Antibiot (Tokyo). 2019 Sep;72(9):702-708. doi: 10.1038/s41429-019-0190-z. Epub 2019 Jun 19. PMID: 31217553. 17: Iqbal S, Hassan S, Hassan A, Ali M, Nazim U, Zaheer E, Ahmed A, Hussain K, Shereen -, Furqan H. In vitro Spectroscopic studies on drug interaction of cefpodoxime proxetil and H2 receptor blockers. Pak J Pharm Sci. 2019 Mar;32(2 (Supplementary)):881-887. PMID: 31103987. 18: Hassan S, Iqbal S, Zaheer E, Hassan A, Hamid S, Ali M, Akram A, Maroof SZ, Abedin S, Khan SJ. Development and validation of RP-HPLC method for simultaneous determination of cefpodoxime proxetil and H2 receptor antagonists in pharmaceutical dosage forms. Pak J Pharm Sci. 2019 Mar;32(2 (Supplementary)):839-844. PMID: 31103980. 19: Mostafa GAE, Al-Otaibi YH, Al-Badr AA. Cefpodoxime proxetil. Profiles Drug Subst Excip Relat Methodol. 2019;44:1-165. doi: 10.1016/bs.podrm.2019.02.001. Epub 2019 Apr 16. PMID: 31029216. 20: Krajcar N, Marić LS, Šarić D, Milić N, Tešović G. Cefpodoxime proxetil as a therapeutic option in switching therapy for infective endocarditis in children: case reports and literature review. J Chemother. 2019 Oct;31(6):354-358. doi: 10.1080/1120009X.2019.1603797. Epub 2019 Apr 22. PMID: 31007148.

View History

Perflubutane

Perflubutane